Achieve Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Common Stock (Tables)

Common Stock (Tables)

12 Months Ended

Dec. 31, 2012


	2012			2011			2010
Risk-free interest rates		0.96	%		1.70	%		2.73	%
Expected dividend yield		0	%		0	%		0	%
Expected life		5.9 years			5.9 years			6.8 years
Expected volatility		95	%		76	%		75	%

Summary of share-based compensation expense


	Years ended December 31,
	2012		2011		2010
	$		$		$
Research and development		899		509		331
General and administrative		1,276		679		311

Total stock-based compensation		2,175		1,188		642

Summary of stock options activity


	Number of Optioned Common Shares			Weighted Average Exercise Price
	#			$
Balance, December 31, 2009		802,871			6.95
Option grants		170,872			15.87
Option cancellations		(7,311	)		104.91
Option exercises		(194,956	)		4.22


Option forfeited	(26,563	)	7.35

Balance, December 31, 2010	744,913		8.74
Option grants	101,600		15.72
Option cancellations	(22,986	)	13.95
Option exercises	(56,228	)	3.88
Option forfeited	(971	)	41.91

Balance, December 31, 2011	766,328		9.82
Option grants	172,650		12.97
Option cancellations	(12,309	)	9.10
Option exercises	(117,347	)	3.94
Option forfeited	(4,541	)	15.26

Balance, December 31, 2012	804,781		11.34

Summary of stock options outstanding regarding the number of ordinary shares issuable upon exercise of outstanding options

Exercise Prices	Number of Options		Weighted- Average Exercise Price $		Weighted- Average Remaining Contractual Life (in years)
$2.69 — $2.85		34,000		2.69		2.82
$2.86 — $3.56		232,600		3.00		2.98
$3.57 — $12.48		68,840		10.12		6.85
$12.49 — $12.81		22,000		12.56		9.46
$12.82 — $13.06		118,750		13.00		9.35
$13.07 — $15.74		43,176		14.26		8.46
$15.75 — $16.40		121,700		15.97		7.95
$16.41 — $17.67		48,500		16.92		8.14
$17.68 — $21.67		39,115		18.95		5.24
$21.68 — $22.28		76,100		22.28		6.90


Total		804,781		11.34		6.26

Summary of stock options outstanding regarding the number of ordinary shares issuable upon exercise of vested options

Exercise Prices	Number of Options		Weighted- Average Exercise Price $		Weighted- Average Remaining Contractual Life (in years)
$2.69 — $2.85		34,000		2.69		2.82
$2.86 — $3.56		232,600		3.00		2.98
$3.57 — $12.48		37,839		8.56		5.10
$12.49 — $12.81		42		12.61		9.91
$12.82 — $13.06		27,214		13.00		9.35
$13.23 — $15.74		20,111		14.48		7.75
$15.75 — $16.40		60,850		15.97		7.95
$16.41 — $17.67		21,906		16.91		8.12
$17.68 — $21.67		38,327		18.90		5.26
$21.68 — $22.28		57,076		22.28		6.90


Total		529,965		9.62		5.00

Summary of restricted stock award activity


	2012					2011
	Stock Awards #			Weighted- Average Grant Date Fair Value $		Stock Awards #		Weighted- Average Grant Date Fair Value $
Outstanding January 1
Granted		180,085			13.01		—		—
Vested		—			—		—		—
Forfeited and expired		(8,000	)		13.00		—		—

Outstanding December 31		172,085			13.01		—		—

Summary of fair value of warrants issued


	Years ended December 31,
	2012			2011			2010
Risk-free interest rates		0.34	%		0.55	%		2.01	%
Expected dividend yield		0	%		0	%		0	%
Expected life		2.8 years			3.8 years			4.8 years
Expected volatility		45	%		76	%		75	%

Computation of basic and diluted net loss attributable to common shareholders per share


	Years ended December 31,
(in thousands except shares and per share amounts)	2012		2011		2010

Numerator

Net loss attributable to common shareholders	$	21,099	$	14,673	$	12,584

Denominator

Weighted average number of common shares outstanding		13,522,723		9,729,340		7,030,903

Basic and diluted net loss per common share	$	1.56	$	1.51	$	1.79

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

- Definition

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References + Details